These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 35628495)

  • 1. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.
    Shin HG; Yang HR; Yoon A; Lee S
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are BiTEs the "missing link" in cancer therapy?
    Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
    Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances of bispecific antibodies in solid tumors.
    Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
    J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
    Zhang M; Lam KP; Xu S
    Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
    Cech P; Skórka K; Dziki L; Giannopoulos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.
    Moon D; Tae N; Park Y; Lee SW; Kim DH
    Immune Netw; 2022 Feb; 22(1):e4. PubMed ID: 35291652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
    Wu Z; Cheung NV
    Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
    Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
    Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies for immune cell retargeting against cancer.
    Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
    Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy.
    Fucà G; Spagnoletti A; Ambrosini M; de Braud F; Di Nicola M
    ESMO Open; 2021 Feb; 6(1):100046. PubMed ID: 33508733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
    Wang L; Jiang H; Yin X; Liang T; Li G; Ding C; Yang M; Zhang L; Liu J; Xu Y
    Front Immunol; 2024; 15():1415834. PubMed ID: 38933272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
    Demaria O; Gauthier L; Debroas G; Vivier E
    Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.